Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Relapse, non-adherence and community follow-up

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Relapse with immediate loss of safety

Suicidal or violent intent, command hallucinations, severe agitation, catatonia, inability to eat or drink, dangerous driving, missing vulnerable dependants or acute physical illness requires same-day crisis and medical intervention.

Action: Use the agreed crisis route, assess ABCDE and specific harm scenarios, reduce access to means and arrange a direct specialist review in the least restrictive safe setting. Contact necessary supporters or safeguarding services proportionately and clarify who owns the next review.

Synopsis

Recognise individual relapse signatures, understand medication and service non-adherence without blame, restore safe treatment collaboratively, and coordinate physical, psychological, substance, social and safeguarding follow-up across community and crisis services.

  • Relapse is a clinically important worsening of symptoms, distress, behaviour or function and should be defined against the person's own recovery baseline.
  • Common early changes include sleep disruption, withdrawal, reduced self-care, suspiciousness, irritability, unusual online activity, substance use and missed appointments, but signatures are individual.
  • Non-adherence is a description of treatment exposure, not a character judgement; explore adverse effects, beliefs, memory, cost, access, stigma, coercion and practical routines.
  • Confirm what was actually taken and stopped, including last oral dose, injection date, clozapine gap, smoking, substances and other medicines, before resuming or switching.
  • Use shared decision making to address the cause: adverse-effect treatment, simplified dosing, reminders, outreach, formulation change or a different therapeutic option may be appropriate.
  • Create a written relapse plan listing personal warning signs, actions, preferred contacts, information-sharing choices, physical red flags and product-specific medication instructions.
  • Community follow-up should measure function, physical health, treatment burden, substances, housing, relationships and occupation rather than medication collection alone.
  • After crisis, review what helped, repair any harmful care experience and perform a warm handover so responsibility does not disappear between services.

Key red flags

Rapid loss of sleep with increasing suspiciousness, agitation, commands or disorganisation can precede dangerous relapse and warrants urgent reassessment.

A missed clozapine supply or a prolonged gap in a long-acting injectable requires product-specific action and must not be restarted casually.

Withdrawal from contact combined with absent food, rent problems, exploitation, fire risk or neglected physical treatment requires active outreach and safeguarding.

New fever, confusion, focal neurology, intoxication or medication toxicity may mimic psychiatric relapse and demands a physical assessment.

Conflict with family or services after coercive care can intensify risk and requires trauma-informed engagement rather than escalating confrontation.

Investigation priorities

01
Relapse timeline and mental stateFirst step

Map change in psychosis, mood, sleep, cognition, behaviour and function against baseline.

Management branches

Early deteriorationAct on the personal signature

Recognised changes in sleep, suspiciousness, self-care, contact or substance use emerge.

  1. Contact the person through agreed channels, assess physiological state and specific harm scenarios and compare change with prior relapse patterns.
  2. Review medicines, exposure, adverse effects, substances, stress and practical needs and involve consented supporters when helpful.
  3. Increase follow-up, psychological and practical support and obtain specialist medication review before the presentation becomes an avoidable crisis.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG178 psychosis and schizophrenia recommendationsRelapse, antipsychotic review, adherence, psychological care and long-term community follow-up.
  • NICE NG181 rehabilitation recommendationsCollaborative care planning, rehabilitation, physical health, transitions and missed-contact principles.
  • NICE CG120 psychosis with substance misuseIntegrated assessment and treatment when substance exposure contributes to relapse.
  • Clozaril tablets summary of product characteristicsInterruption, re-titration, registered monitoring and acute clozapine safety requirements.
  • GMC decision making and consentSupported decisions, capacity and collaborative treatment change.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom